ClinicalTrials.gg
WithdrawnNCT02842541Updated Sep 15, 2016

Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema

A Phase 1 interventional study of EBI-031 in Diabetic Macular Edema, sponsored by Eleven Biotherapeutics. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-15.

Sponsored by Eleven Biotherapeutics · Phase 1, Interventional, and Treatment

Why this study was withdrawn
New study planned.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to evaluate the safety, tolerability, immunogenicity, and pharmacokinetics of up to 3 dose levels of EBI-031 given as an intravitreal injection in subjects with diabetic macular edema. There are two arms to the study, a single dose arm (1 dose) and a repeat dose arm (1 dose each month for 3 months). Eligible subjects will initially enroll in the single dose arm and 3 to 6 subjects will be dosed at each of the 3 dose levels. Safety will be assessed over the 28 days after the single dose prior to moving to the next higher dose level. Once all subjects in the single dose arm have been dosed with EBI-031 and the safety has been assessed eligible subjects will begin enrolling in the repeat dose arm. Subjects in the repeat dose arm will receive one dose each month for 3 months and will be assessed for safety. Escalation to the next higher dose will occur once it is determined safe to proceed to the next dose level. Six subjects will be dosed at each of the 3 dose levels.

02

Conditions studied

  • Diabetic Macular Edema

Browse trials for

03

In context

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Lead sponsor

Eleven Biotherapeutics is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Give written voluntary and any authorizations required by local law
  • Have a diagnosis of Type 1 or 2 diabetes mellitus
  • Have decreased vision determined primarily to be the result of DME in the study eye
  • Mean central foveal thickness on Spectral Domain Ocular Coherence Tomography (SD-OCT)> 325 in the study eye within 2 weeks of dosing
  • Have best corrected Early Treatment of Diabetic Retinopathy Study (ETDRS) letter score of \<73 (\~20/40) and >19 (\~20/400) in the study eye within 2 weeks of dosing.

Exclusion criteria

Exclusion Criteria:

  • Female that is pregnant and lactating
  • Any prior history of anti-interleukin 6 (anti-IL-6) treatment, for example: tocilizumab, sirukumab, sarilumab, olokizumab
  • Any concurrent biologics for immune disease such as anti-tumor necrosis factor (TNF): Enbrel (etanercept), Humira (adalimumab), Remicade (infliximab); an anti-interleukin 12 (anti-IL-12): Stelara (ustekinumab); or an anti-interleukin 1 (anti-IL-1): Kineret (anakinra), Ilaris (canakinumab), Arcalyst (rilonacept).
  • Unstable, uncontrolled diabetes defined as (HbA1C)≥10.5% within 3 months prior to dosing of EBI-031
  • Received intravitreal anti-vascular endothelial growth factor (anti-VEGF) such as Eylea (aflibercept) within 8 weeks, Lucentis (ranibizumab) and Avastin (bevacizumab) within 4 months prior to EBI-031
  • Significant renal disease, liver disease, or acute congestive heart failure
  • History of myocardial infarction (MI), stroke, or (TIA)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Single dose arm

    Subjects will receive a single intravitreal dose of EBI-031

    Drug: EBI-031

  • Experimental
    Repeat dose arm

    Subjects will receive an intravitreal dose of EBI-031 monthly for 3 months

    Drug: EBI-031

Interventions

06

What researchers measure

Primary outcomes

  1. Safety, tolerability, and immunogenicity as measured by adverse events and anti-drug antibody development of single and repeat doses of EBI-031

    Number of Participants With Abnormal Laboratory Values, Adverse Events, and/or antibodies to EBI-031

    Time frame: Measure over the 84 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2016, a primary completion of Oct 2017 and a completion of Feb 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2016
First posted
Jul 25, 2016
Start
Sep 2016
Primary completionEst.
Oct 2017
CompletionEst.
Feb 2018
Last update
Sep 15, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02842541
Lead sponsor
Eleven Biotherapeutics
Responsible party
Sponsor
First posted
Jul 25, 2016
Start date
Sep 2016
Primary completion
Oct 2017 (estimated)
Completion
Feb 2018 (estimated)
Last update
Sep 15, 2016

Study contacts

Karen Tubridy
study director · Eleven Biotherapeutics
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vamikibart

Start the discussion